Skip to content
The Policy VaultThe Policy Vault

Ilaris (canakinumab) — Highmark

Adult-Onset Still’s Disease (AOSD)

Initial criteria

  • age ≥ 18 years (if <18, refer to SJIA criteria)
  • diagnosis of Adult-Onset Still’s Disease (AOSD)
  • prescribed by or in consultation with a rheumatologist

Reauthorization criteria

  • member is tolerating therapy AND has experienced disease improvement OR delayed disease progression